Objective To investigate the anti-proliferative effect of rosiglitazone and its relationship to
peroxisome proliferator-activated receptor γ (PPARγ) in human breast cancer cell line MDA …

Breast cancer, especially triple-negative breast cancer, is one of the deadliest cancers in
women. To date, there is a lack of a good therapeutic regimen for it. PPARγ has been …

Peroxisome proliferator‐activated receptor γ (PPARγ) is expressed in various types of
human cancer cells including leukaemia cells, and activation of PPARγ can inhibit cancer …

Breast cancer (BC) is the most frequent cancer in women around the world. Tumor cells
have several mechanisms of resistance to chemotherapy treatment, so the relevance of …

The aim of the study was to evaluate the antitumor effects of the PPARγ agonist rosiglitazone
on the human retinoblastoma. The cell biological behavior was detected, specifically, the …

Background Activation of peroxisome proliferator-activated receptors γ (PPARγ) induces
diverse effects on cancer cells. The thiazolidinediones (TZDs), such as troglitazone and …

Objective To explore the expression of Peroxisome Proliferator-activated Receptor-gamma
(PPAR-gamma) in QBC939 and the effects of PPAR-gamma activated by its ligand …

Objective To investigate the apoptotic effects of peroxisome proliferator-activated receptor γ
(PPAR-γ) agonist rosiglitazone (RGZ) on leukemia HL-60 cells. Methods Cell apoptosis was …

Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the nuclear hormone
superfamily and has multiple endogenous and pharmacological ligands, including 15-deoxy …

Purpose: Peroxisome proliferator-activated receptor γ (PPARγ) is a steroid nuclear receptor
that is activated by natural compounds such as specific fatty acids and synthetic drugs such …